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Arylimidamides (AIAs) have shown outstanding in vitro potency against intracellular kinetoplastid parasites, and the AIA 2,5-
bis[2-(2-propoxy)-4-(2-pyridylimino)aminophenyl]furan dihydrochloride (DB766) displayed good in vivo efficacy in rodent
models of visceral leishmaniasis (VL) and Chagas’ disease. In an attempt to further increase the solubility and in vivo antikineto-
plastid potential of DB766, the mesylate salt of this compound and that of the closely related AIA 2,5-bis[2-(2-cyclopentyloxy)-4-
(2-pyridylimino)aminophenyl]furan hydrochloride (DB1852) were prepared. These two mesylate salts, designated DB1960 and
DB1955, respectively, exhibited dose-dependent activity in the murine model of VL, with DB1960 inhibiting liver parasitemia by
51% at an oral dose of 100 mg/kg/day  5 and DB1955 reducing liver parasitemia by 57% when given by the same dosing regi-
men. In a murine Trypanosoma cruzi infection model, DB1960 decreased the peak parasitemia levels that occurred at 8 days
postinfection by 46% when given orally at 100 mg/kg/day  5, while DB1955 had no effect on peak parasitemia levels when ad-
ministered by the same dosing regimen. Distribution studies revealed that these compounds accumulated to micromolar levels
in the liver, spleen, and kidneys but to a lesser extent in the heart, brain, and plasma. A 5-day repeat-dose toxicology study with
DB1960 and DB1955 was also conducted with female BALB/c mice, with the compounds administered orally at 100, 200, and 500
mg/kg/day. In the high-dose groups, DB1960 caused changes in serum chemistry, with statistically significant increases in serum
blood urea nitrogen, lactate dehydrogenase, aspartate aminotransferase, and alanine aminotransferase levels, and a 21% de-
crease in body weight was observed in this group. These changes were consistent with microscopic findings in the livers and kid-
neys of the treated animals. The incidences of observed clinical signs (hunched posture, tachypnea, tremors, and ruffled fur)
were more frequent in DB1960-treated groups than in those treated with DB1955. However, histopathological examination of
tissue samples indicated that both compounds had adverse effects at all dose levels.
Leishmaniasis and Chagas’ disease (CD) are two widespreadneglected diseases that affect impoverished areas of developing
countries. Visceral leishmaniasis (VL) accounts for approximately
25% of the estimated 2 million new cases of leishmaniasis that
occur annually. VL is caused by the protozoan parasites Leishma-
nia donovani in India and Africa, L. infantum in the Mediterra-
nean region, and L. chagasi in the countries of the New World
where the disease is endemic. Symptomatic VL results in hepato-
splenomegaly, anemia, wasting, and susceptibility to other infec-
tions, which are almost always fatal if left untreated. Despite ad-
vances in treating VL on the Indian subcontinent, which include
the registration of both the oral drug miltefosine (26) and the
injectable antibiotic paromomycin (25), as well as the demonstra-
tion of the high efficacy of single-dose liposomal amphotericin B
(24), these drugs are often too expensive or less effective when
used in Africa or Brazil (5, 15–17). In addition, miltefosine is
teratogenic (4, 20). Considering these weaknesses of existing
agents used against VL, a new orally available, inexpensive, small-
molecule antileishmanial drug is needed that would display high
efficacy when given in a short course, either alone or in a combi-
nation. Likewise, new therapies are urgently needed for CD. CD is
caused by the protozoan parasite Trypanosoma cruzi and affects
more than 10 million people in the poorest areas of Latin America,
as well as in other geographic regions. The reduviid vector trans-
mits the parasite in Latin America; cases occurring in other re-
gions are due mainly to the migration of infected individuals to
areas such as the United States, Canada, and many European and
some Western Pacific countries (9). CD therapy is based on two
nitroaromatic drugs, nifurtimox and benznidazole (Bz), that are
recommended for all acute-stage, early-chronic-stage, and reacti-
vated cases (2, 6). However, both drugs are far from ideal and give
variable results, depending on the area where the disease is en-
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demic; present considerable toxicity; are administered over 30 or
more days; and are not very effective against the later chronic
phase of CD or against naturally resistant strains (7, 21). Another
challenge for CD therapy is related to blood prophylaxis in areas
where the disease is endemic since the only drug used, gentian
violet, is toxic, gives blood a purple color, and may stain the skin
and mucosa of recipients (6, 7). Thus, a new drug candidate
against CD should display activity against a large panel of parasite
isolates, including bloodstream forms, intracellular forms, and
resistant organisms; should present oral efficacy equal to or better
than that of Bz; and should exhibit low toxicity.
Our previous efforts have identified arylimidamides (AIAs) as
compounds with outstanding in vitro antileishmanial (8, 22) and
anti-T. cruzi (12, 18, 19) activities. In addition to excellent in vitro
antileishmanial potency, the AIA hydrochloride salt 2,5-bis[2-(2-
propoxy)-4-(2-pyridylimino)aminophenyl]furan (DB766) dis-
played good efficacy in both murine and hamster models of VL
(27), was as active as Bz in experimental models of T. cruzi infec-
tion (3), was not mutagenic in the Ames test, and did not have an
effect on the serum chemistry of mice when given orally at a dose
of 100 mg/kg/day  5, although higher dose levels were not tested
due to the limited aqueous solubility of DB766 (27). In an effort to
advance members of this class of compounds toward clinical de-
velopment for the treatment of VL and CD, more-soluble AIA
salts were synthesized (Fig. 1 shows their structures), including
DB1960 (mesylate salt of DB766) and DB1955 {mesylate salt
of DB1852, 2,5-bis[2-(2-cyclopentyloxy)-4-(2-pyridylimino)am-
inophenyl]furan hydrochloride}. We report here the in vitro and
in vivo antileishmanial and anti-T. cruzi activities, pharmacoki-
netic (PK) profiles, and in vivo toxicities of these AIA mesylate
salts.
MATERIALS AND METHODS
AIAs. The preparation and characterization of DB766 (27) and DB1852
(1) have been reported earlier. For the procedures used for the synthesis of
DB1955 and DB1960, along with the characterizations of these com-
pounds, see the supplemental material.
Solubility measurements. The water solubility of the AIA salts of in-
terest was measured by the method of Zhou et al. (28), with some modi-
fications. Briefly, serial dilutions of compounds were prepared in di-
methyl sulfoxide and read at 370 nm using a SpectraMax Plus 384
spectrophotometer (Molecular Devices, Sunnyvale, CA) to construct a
standard curve. A saturated solution of each compound containing some
undissolved solid was then prepared and centrifuged. The supernatant
from the saturated solution was collected, diluted 1:40 with water, and
read at 370 nm as described above. The water solubility of each compound
was determined by interpolation from the appropriate standard curve.
In vitro susceptibility assays. The potency of AIAs and control com-
pounds for VL (amphotericin B) and for CD (Bz) against intracellular L.
amazonensis and L. donovani and bloodstream trypomastigotes and amas-
tigotes of T. cruzi strain Y was determined as follows. Intracellular Leish-
mania assays were conducted as described previously for L. donovani (29)
and L. amazonensis (13). For the analysis of the effects of the compounds
upon bloodstream trypomastigote forms, 5  106/ml parasites were in-
cubated for 24 h at 37°C in RPMI 1640 medium supplemented with 10%
fetal calf serum in the presence or absence of serial dilutions of each
compound. Parasite death was determined by light microscopy using a
Neubauer chamber, which allows the direct visualization and quantifica-
tion of the number of motile and live parasites, and then 50% inhibitory
concentrations (IC50s) were calculated (3). For the analysis of the effects
of compounds on intracellular forms of T. cruzi after 24 h of parasite-host
cell interaction (10:1 ratio), infected cardiac cultures were washed to re-
move extracellular parasites and then maintained at 37°C in a 5% CO2–
95% air atmosphere in the presence of nontoxic (to cardiac cells) concen-
trations of each compound with replacement of the medium (containing
the respective AIA) every 24 h. Infected cultures lacking a test compound
were used as controls. After 48 h, all cultures were fixed and stained with
Giemsa solution. The endocytic index was used to compare compound
activities and was calculated by multiplying the percentage of infected cells
by the mean number of parasites per infected cell. IC50s were calculated as
previously reported (3).
Primary cultures of embryonic cardiomyocytes were obtained from
Swiss mice and purified as previously described (3). The toxicities of the
test compounds for cardiac cell cultures (3) and murine peritoneal mac-
rophages (27) were measured as described previously.
DNA binding experiments. Tm studies were performed as previ-
ously described (22).
In vivo evaluation of antileishmanial efficacy. In vivo murine VL
model experiments were carried out as described previously (13), with
some modifications for this study. Briefly, BALB/c mice were inoculated
intravenously with 5  107 LV82 promastigotes. After infection on day 0,
mice were marked for individual identification and randomly sorted into
groups of 4. The treatment was started 1 week after infection (day 7) and
continued for 5 days (days 7 to 11). In these experiments, compounds
were dissolved in water and given either intraperitoneally (i.p.) or orally
(p.o.) by gavage. One group received water as an untreated control, one
group received miltefosine at 10-mg/kg/dose as a positive control, and
other groups received either DB1852 at 10 or 30 mg/kg/dose i.p., DB1955
at 100 or 200 mg/kg/dose p.o., or DB1960 at 50, 100, or 200 mg/kg/dose
p.o. On day 14 (i.e., 3 days after the last dose), animals were euthanized
and Giemsa-stained liver smear slides were prepared. The number of
amastigotes per 200 cell nuclei was determined by microscopy, and para-
site burdens, expressed in Leishman-Donovan units (LDU), were calcu-
lated by using the equation LDU  number of amastigotes per 1,000 cell
nuclei  total liver weight (grams). Compound efficacy was determined
by comparing the LDU counts of mice in the treated and untreated
groups.
In vivo evaluation of anti-T. cruzi activity. Male Swiss mice were
obtained from the Fundação Oswaldo Cruz (FIOCRUZ) animal facilities
(Rio de Janeiro, Brazil). Mice were housed at a maximum of 8 per cage
and kept in a conventional room at 20 to 24°C under a 12/12-h light-
dark cycle. The animals were provided with sterilized water and chow
ad libitum. Infection was performed by i.p. injection of 104 blood-
stream trypomastigotes of strain Y. Animals (18 to 21 g) were divided
into the following groups: uninfected (noninfected and nontreated),
untreated (infected with T. cruzi but nontreated), and treated (infected
and treated i.p. or p.o. at 12.5 to 100 mg/kg/day with DB1955 and
FIG 1 Structures of DB766, DB1852, DB1955, and DB1960.
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DB1960 or at 100 mg/kg/day with Bz). For DB1955 and DB1960, mice
received a 0.1-ml i.p. injection or a 0.2-ml oral dose, with five daily
consecutive doses, starting at the onset of parasitemia. For Bz treat-
ment, infected mice received a 0.2-ml oral dose (gavage) following the
therapeutic schemes described above. Parasitemia was individually
checked by direct microscopic counting of parasites in 5 l of blood as
described previously (3). At different days postinfection, body weight
was measured and the number of deaths was recorded daily until 30
days posttreatment and expressed as a percentage of the cumulative
mortality rate. All compounds were directly diluted with water.
Single-dose PKs and tissue distribution studies with uninfected
mice. Male Swiss Webster mice (20 to 30 g; n  3 per time point) were
given DB1955 or DB1960 via oral gavage at a dose volume of 5 ml/kg.
Compounds were dissolved in sterile water to form a clear solution at 20
mM. Terminal blood and tissue (liver, spleen, kidney, heart, and brain)
samples were collected at selected time points from 1 h to 72 h postdose
and further processed for quantification of AIAs as described below using
previously described methods (27), with modifications. Briefly, liver,
spleen, kidney, heart, and brain samples from mice were weighed, diluted
with 2 volumes of water (assuming that 1 g of wet tissue equals a volume
of 1 ml), and then homogenized. Tissue homogenates or plasma samples
were extracted and prepared for high-performance liquid chromatogra-
phy (HPLC)/UV or HPLC-tandem mass spectrometry (MS/MS) analysis
as previously described (27). HPLC/UV analyses of DB1960 and DB1955
from tissue homogenates were performed using a reversed-phase analyt-
ical column (Zorbax Bonus-RP, 2.1 by 50 mm, 3.5 m; Agilent, Palo Alto,
CA) and by monitoring analytes at a wavelength of 368 nm. The calibra-
tion curves ranged from 0.1 to 100 M. HPLC-MS/MS analyses of
DB1960 and DB1955 in plasma samples were performed with an Applied
Biosystems (Foster City, CA) API 3000 triple quadrupole mass spectrom-
eter equipped with a Turbo IonSpray interface (MDS Sciex, San Fran-
cisco, CA). The characteristic SRM transitions for DB1960 and DB1955
were m/z 575.3 ¡ 454.1 and 627.5 ¡ 610.4, respectively, in positive-ion
mode. The calibration curve for DB1960 and DB1955 ranged from 10 to
4,000 nM using a quadratic equation with 1/x weighting.
Toxicity and toxicokinetic evaluations in female BALB/c mice. Sin-
gle-dose escalation and 5-day repeat-dose toxicity experiments were per-
formed using 7- to 8-week-old BALB/c female mice. The no-observable-
adverse-effect levels (NOAELs) and maximum tolerated doses (MTDs) of
DB1955 and DB1960 were determined in female BALB/c mice following a
single p.o. administration and five daily p.o. administrations. Dose for-
mulations were prepared fresh daily under yellow light by dissolving ap-
propriate amounts of compound in sterile water to achieve the target
concentrations. The dosing volume was 10 ml/kg. For the single-dose
escalation experiment, mice (n  2 for each dose level per compound)
were administered 0, 50, 100, 200, or 500 mg/kg and observed for 3 days.
Since no adverse effects were observed in any of the groups, 100-, 200-,
and 500-mg/kg dose levels were selected to conduct a 5-day repeat-dose
experiment with the two compounds. In a repeat-dose range-finding
study, DB1955 and DB1960 were administered to female BALB/c mice for
5 consecutive days at the selected doses. Mice were euthanized on day 6 for
the main necropsy and day 12 for the recovery necropsy. For the experi-
mental design of this range-finding study, see Table S1 in the supplemen-
tal material. A satellite group of mice were also included for evaluation of
plasma drug levels and toxicokinetic parameters. Plasma drug levels were
evaluated at 0.5, 1, and 6 h postdose on day 1 and predose and at 0.5, 1, 4,
6, and 24 h postdose on day 5. Body weights were recorded prior to day 1
and prior to each necropsy. Clinical hematology and serum chemistry
were measured for blood samples collected 1 day after the last dose (day 6)
prior to necropsy. Histopathologic examination of tissues retained in 10%
neutral buffered formalin was performed by a board-certified veterinary
pathologist. Toxicokinetic analysis was conducted using WinNonlin ver-
sion 5.2 Professional by noncompartmental modeling. The following pa-
rameters were determined: the maximal plasma drug concentration
(Cmax), time to maximum plasma drug concentration (Tmax), the area
under the plasma drug concentration-time curve (AUC) from 0 to 6 h on
days 1 and 5 (AUC0-6), and the AUC0-24 on day 5. The terminal elimina-
tion half-life (t1/2) was also determined in groups that had at least three
sample collection times after the Tmax.
Statistical analysis. Body weights, organ weights, and clinical pathol-
ogy data were evaluated by one-way analysis of variance (ANOVA), fol-
lowed by Dunnett’s test (if the ANOVA result was significant). All other
numeric parameters were evaluated by Student’s t test unless specified
otherwise. For clinical pathology data, values that were below the detec-
tion threshold were not included in the statistical evaluation.
RESULTS
Solubility of AIA salts. Our initial observations suggested that
mesylate salts DB1955 and DB1960 were more soluble than their
corresponding hydrochloride salts DB1852 and DB766. Measure-
ment of the solubilities of these AIA salts in water indicated that
DB1955 was 3.1-fold more soluble than DB1852 (solubility limits
of 54.2 mM and 16.7 mM, respectively), while DB1960 was 5.3-
fold more soluble than DB766 (solubility limits of 55.5 mM and
10.4 mM, respectively).
In vitro antileishmanial and anti-T. cruzi efficacy studies
with DB766, DB1852, DB1955, and DB1960. The in vitro antil-
eishmanial activities of DB766, DB1852, DB1955, and DB1960 are
shown in Table 1. Dose-response curves were steeper for DB1960
than for DB1955 (IC90  0.038  0.007 M and 1.7  0.2 M
[mean  standard error], respectively). As expected, the biologi-
cal activity of the hydrochloride salts was nearly identical to the
activity of the corresponding mesylate salts in the intracellular
Leishmania assay and the peritoneal macrophage toxicity assay.
DB1852 did not display DNA binding, as judged by its negligible
Tm value obtained using poly(dA·dT)2 DNA, consistent with the
Tm data obtained for this compound using T. cruzi kinetoplast
DNA (10). The mesylate salt of DB1852, DB1955, also gave no
Tm increase. In a similar manner, DB766 and DB1960 have the
same Tm values within the range of experimental error, indicat-
ing that the anion does not play a significant role in DNA interac-
tions of these compounds, as expected. The low Tm values of all
four compounds suggest that DNA binding does not play a signif-
icant role in their biological effects in the test systems. Evaluation
of these compounds against T. cruzi revealed that although all of
the AIAs studied (DB766, DB1955, and DB1852) displayed similar
effects upon bloodstream trypomastigotes, DB766 was the most
active against intracellular forms, exhibiting about 100 times more
potency than the reference drug Bz (Table 2).
TABLE 1 In vitro antileishmanial activities and Tm values of DB766,
















DB766c 0.036  0.005 0.087  0.015 2.8  0.8 6.0
DB1852 0.16  0.03 0.17  0.06 6.9  0.9 1.0
DB1955 0.25  0.08 0.16  0.03 8.3  1.2 1.1
DB1960 0.020  0.002 0.056  0.019 4.7  0.8 5.3
Amphotericin B 0.05  0.01 0.15  0.03 3.9  2.1 NDd
a The values are means  standard errors of at least three independent experiments.
b Tm
(AT), increase in thermal melting of poly(dA·dT)2 on addition of the compound
to a saturation ratio; the reproducibility is 0.5°C.
c The values for DB766 are from reference 27.
d ND, not determined.
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In vivo antileishmanial efficacies of DB1852, DB1955, and
DB1960. In vivo evaluation of DB1852 given at 5  30 mg/kg/day
by the i.p. route showed 61%  5% inhibition of liver parasitemia
(Fig. 2A), which was comparable to the previously reported in vivo
efficacy of DB766 (63%  11%) given by the same dosing regimen
and route (27). Considering that DB766 showed in vivo activity in
both the murine and hamster VL models when given orally (27),
the efficacy of the more soluble mesylate salts of both of these
compounds was examined in the murine model of VL by the oral
route. DB1955 was evaluated at 5  100 mg/kg/day and 5  200
mg/kg/day, giving 57%  5% and 78%  4% inhibition of liver
parasitemia, respectively (Fig. 2B). DB1960 was tested at oral
doses of 5  50 mg/kg/day, 5  100 mg/kg/day, and 5  200
mg/kg/day, resulting in 29%  4%, 51%  6%, and 93%  6%
inhibition of liver parasitemia, respectively (Fig. 2C). These com-
pounds were also evaluated in hamsters infected with L. donovani
and displayed good activity in this model as well (A. Srivastava and
D. Kyle, unpublished data).
In vivo trypanocidal efficacy of DB1955 and DB1960. When
given under different treatment schemes (five consecutive daily
i.p. and p.o. doses), DB1955 did not show any trypanocidal effi-
cacy as assessed by the peak parasitemia levels that occurred at 8
days postinfection (Fig. 3A). Instead, some schemes resulted in a
slight increase in parasitemia compared to that in untreated ani-
mals (Fig. 3A). Regarding the mortality rate, only the 25-mg/kg
i.p. dose resulted in 100% survival while the other doses (12.5 and
50 mg/kg/day) reduced mortality rates only slightly or increased
mortality rates (100 mg/kg/day p.o.; data not shown). DB1960 was
tested at oral doses of 5  12.5 to 100 mg/kg/day. Although the
12.5- and 25-mg/kg doses neither reduced parasitemia nor pro-
tected against death, treatments with DB1960 at 50 and 100 mg/
kg/day resulted in 28%  7% and 46%  10% reductions of peak
parasitemia, respectively (Fig. 3B). While DB1960 at 50 mg/kg/
day did not reduce mortality rates, administration of this com-
pound at 100 mg/kg/day resulted in an about 35% reduction in the
mortality rates (data not shown), showing less activity than DB766
in experimental models of acute T. cruzi infection (3). The admin-











DB766b 0.060  0.004 0.025  0.006 18  3
DB1852c 0.060  0.01 0.538  0.21 24  11
DB1955 0.072  0.0007 0.18  0.003 1.18  0.8
Bz 12.94  1.93 2.77  1.96 997
Pentamidine 32 NDd ND
a The values are means  standard errors of at least three independent experiments.
b The values for DB766 are from reference 3.
c The values for DB1852 are from reference 11.
d ND, not determined.
FIG 2 Liver parasite burdens (LDU counts) of BALB/c mice infected with LV82 and treated with AIAs or miltefosine as determined by microscopy (n  4).
Panels: A, LDU counts of mice treated with DB1852 i.p.; B, LDU counts of mice treated with DB1955 p.o.; C, LDU counts of mice treated with DB1960 p.o.
Miltefosine was given p.o. in each case. *, P  0.05 (compared with untreated control); **, P  0.01 (compared with untreated control).
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istration of Bz not only suppressed parasitemia but also resulted in
100% animal survival in both sets of assays (Fig. 3). Regarding
body weight, neither DB1955 nor DB1960 was able to restore the
weight loss induced in mice by acute T. cruzi infection, in contrast
to Bz treatment (data not shown).
PKs and tissue distribution of DB1955 and DB1960 in mice.
The average plasma and tissue drug concentrations in uninfected
mice given a single p.o. dose (100 mol/kg or approximately 76
mg of salt/kg for DB1955 and 78 mg of salt/kg for DB1960) of
DB1955 or DB1960 were determined to confirm their potential as
orally active drug candidates. Both molecules quickly appeared in
plasma with a Tmax of around 1 to 2 h, followed by a rapid decline
during the distribution phase and a slower terminal elimination
phase with t1/2s ranging from 14 to 18 h (Fig. 4 and Table 3). The
maximal plasma DB1955 concentration was approximately 3-fold
greater than that of DB1960 (3.13 M versus 1.07 M); however,
similar plasma exposures (AUC) were observed due to the longer
t1/2 of DB1960 (18 h versus 14 h).
Average tissue DB1955 (Fig. 4A) or DB1960 (Fig. 4B) concen-
trations after a single oral administration in uninfected mice were
determined using liver, spleen, kidney, heart, and brain tissue ho-
mogenates. As expected based on our previous observations with
the AIAs DB745 and DB766 (27), the highest drug concentrations
were detected in the spleen and liver, which are target organs for
antileishmanial/anti-T. cruzi chemotherapy. The maximum
DB1955 concentrations were 6.0, 2.3, and 1.9 g/g (or 9.5, 3.6, and
3.1 M) in the liver, spleen, and kidney, respectively. The maxi-
mum DB1960 concentrations were 6.8, 9.9, and 3.2 g/g (or 11.9,
17.3, and 5.5 M) in the liver, spleen, and kidney, respectively.
DB1960 was also detected in the heart at a maximum concentra-
tion of 1.4 g/g (or 2.5 M) but was below the lower limit of
quantitation (LLOQ) (0.06 g/g or 0.1 M) in the brain, except
for one animal. In contrast, DB1955 was not detected in either the
brains or the hearts of mice receiving this molecule (except that
the compound was detected in the heart of one animal). The lower
levels of DB1955 in the heart may be related to its poor efficacy in
our T. cruzi-infected mouse model since this organ is one of the
main targets of this parasite.
Single-dose range-finding toxicology study summary. A sin-
gle-dose range-finding study was conducted with DB1955 and
FIG 3 Parasitemia levels of T. cruzi-infected mice treated with five consecutive daily doses of DB1955 and DB1960 via the i.p. and p.o. routes. The results of a
representative study examining the efficacy of 12.5- to 100-mg/kg DB1955 (A; n  5 per group) and DB1960 (B; n  8 per group) are shown, with Bz given p.o.
(100 mg/kg/day) used as the reference drug. Symbols and error bars denote the means and standard errors.
FIG 4 Plasma and tissue DB1955 (A) and DB1960 (B) concentrations of mice
after a single oral administration of 100 mol/kg (or 76 mg of salt/kg for
DB1955 and 78 mg of salt/kg for DB1960). Tissue drug concentrations were
calculated assuming that 1 g of wet tissue equals a volume of 1 ml. Symbols and
error bars denote the means and standard errors, respectively, of triplicate
determinations. Spleen DB1955 concentrations at 1 and 24 h were from du-
plicate determinations.
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DB1960 and 7- to 8-week-old female BALB/c mice at oral doses of
50, 100, 200, and 500 mg/kg. No adverse effects were observed in
any of the groups. Based on the results of this study, the MTD after
a single oral dose administration was estimated to be at least 500
mg/kg.
Five-day repeat-dose range-finding toxicology and toxicoki-
netic study. Clinical findings and body weight changes. All ani-
mals in the DB1955 groups survived for the duration of the repeat-
dose range-finding study. No overt responses were observed in the
low-dose DB1955 group, and most of the animals in the medium-
and high-dose groups also appeared normal. However, single an-
imals in the medium-dose group showed lacrimation, dyspnea,
and hypoactivity on day 5 or 6, while hunched posture (one ani-
mal), tachypnea (two animals), and ruffled fur (three animals)
were observed in the high-dose group. Compared with the control
group, there were no changes in body weight on day 6 in animals
treated with DB1955 but on day 12, mice in the 500-mg/kg group
had a 14% body weight reduction that was statistically significant.
The average body weights of all groups are given in Table S2 in the
supplemental material.
The incidences of observed clinical signs were generally higher
in DB1960-treated groups than in those treated with DB1955, and
the animals in the high-dose DB1960 recovery group were eutha-
nized in moribund condition (on day 6) due to hypoactivity,
hunched posture, and tremors. All other animals treated with
DB1960 survived to their scheduled necropsy. Mice treated with
DB1960 displayed tremors, ruffled fur, and tachypnea in a dose-
dependent manner, with the effects occurring in an increasing
number of animals per group as the dose was escalated. On day 6,
mice treated with DB1960 at 500 mg/kg had a 21% reduction in
body weight that was statistically significant. Except for those
mentioned above, there were no other changes in body weight that
could be attributed to treatment with DB1955 or DB1960.
Hematology and clinical chemistry. DB1955 and DB1960
treatments had little effect on the hematocrit (HCT), hemoglobin
(HGB) level, red blood cell (RBC) count, or white blood cell
(WBC) count, although there was a statistically significant de-
crease in the HCT and the HGB level in mice in the medium-dose
DB1960 group compared with those in the control group. The
platelet count (PLC) was also decreased in mice treated with
DB1960, and the changes in animals in the medium- and high-
dose groups were statistically significant. The percentage of neu-
trophils (PNS) was increased on day 6 by 3-fold in mice treated
with high-dose DB1960, possibly due to tissue damage and asso-
ciated inflammation. A summary of these parameters is given in
Table 4. By day 12, no changes in the above parameters were ob-
served in animals treated with either test drug compared to those
in untreated control animals (data not shown). Hematology pa-
rameters are not available for mice in the high-dose DB1960 re-
covery group since these animals were euthanized in moribund
condition on day 6.
Clinical chemistry measurements are provided in Table 5.
Changes in lactate dehydrogenase (LDH), aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT), and cholesterol
(CHO) levels were statistically significant in the high-dose
DB1960 group compared with those of the controls. DB1960 also
produced a 5-fold increase in the blood urea nitrogen (BUN) level
in the high-dose DB1960 group compared with that in the control
group. Triglycerides (TRI) were decreased on day 6 in a dose-
dependent manner in mice treated with either DB1955 or
DB1960, and this decrease was statistically significant for mice in
all DB1960 groups and those in the high-dose DB1955 groups.









(h·mol/liter) MRTlast (h) t1/2 (h)
DB1955 100/76 3.1  1.0 2 17.6  5.5 17.8 12 14
DB1960 100/78 1.07  0.35 1 18.4  1.7 19.5 19 18
a Milligrams of salt per kilogram of body weight.
b The values are means  standard errors.








(103/l) PLC (103/l) PNS (%)
Vehicle,a 0 40.8  1.09 13.5  0.30 9.18  0.265 14.8  0.53 3.14  0.434 857  183.6 19.8  4.32
DB1955
100a 40.0  1.68 13.3  0.44 8.94  0.247 14.8  1.21 3.62  0.658 958  76.2 16.9  5.59
200a 39.6  3.42 13.3  1.19 8.91  0.778 14.4  1.29 3.21  1.417 832  191.9 16.6  3.45
500a 37.6  1.84 12.6  0.31 8.46  0.297 14.7  0.75 3.92  1.068 832  69.2 15.5  1.65
DB1960
100a 39.5  1.76 13.1  0.58 8.91  0.317 15.2  1.29 3.35  0.551 727  119.4 16.6  5.13
200a 36.7  1.46c 12.2  0.41c 8.29  0.363 15.3  1.80 2.06  0.666 577  61.8d 26.4  7.02
500b 38.4  2.23 12.7  0.76 8.80  0.551 15.1  0.82 4.04  1.079 604  136.7d 63.6  7.60d
a The values are means  standard deviations of experimental groups of five animals.
b The values are means  standard deviations of experimental groups of eight animals.
c Significant difference from control (P  0.05).
d Significant difference from control (P  0.01).
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Statistically significant decreases in albumin (ALB) and the albu-
min/globulin ratio (AGR) were observed in the medium- and
high-dose DB1960 groups, suggesting malnutrition possibly due
to enteropathy. On day 12, the AST and ALT levels remained
elevated in mice treated with high-dose DB1955, while other pa-
rameters for DB1960 and DB1955 appeared to return to control
levels by day 12 (data not shown). As with the hematology param-
eters, clinical chemistry values were not available for mice in the
high-dose DB1960 recovery group since these animals were eutha-
nized earlier in the study.
Gross necropsy findings and organ weights. No gross nec-
ropsy findings could be attributed to DB1955 treatment. At the
main necropsy (day 6), tissue changes that were attributed to
treatment with DB1960 included discolored dark or pale kidneys;
a discolored dark, pale, yellow, or mottled liver; discolored dark or
yellow lymph nodes; a discolored dark spleen; discolored orange
or red stomach contents; a discolored dark and pale thymus; and a
small thymus. These changes were observed mainly in mice
treated with DB1960 at 500 mg/kg. At the recovery necropsy (day
12), tissues in all groups appeared normal. There was no recovery
necropsy for mice in the high-dose DB1960 group since they were
euthanized in moribund condition on day 6. Most organ weights
appeared to be within control ranges (data not shown).
Histopathology. At the main necropsy, treatment-related
changes associated with DB1955 were present in the stomach,
mesenteric lymph nodes, and bone marrow smears (cytology) at
all three dose levels. Forestomach epithelial hyperplasia was pres-
ent at all dose levels, and inflammation, ulceration, and hyperkera-
tosis were present in the high-dose group only. The bone marrow
smears had an increased myeloid/erythroid cell ratio in the medium-
and high-dose groups. Treatment-related changes associated with
all dose levels of DB1960 at the main necropsy were present in the
spleen, liver, kidneys, duodenum, jejunum, ileum, mesenteric
lymph nodes, bone marrow smear, bone marrow histology (ster-
num section), thymus, and pancreas. The kidneys showed renal
nephrosis, which was present in the medium- and high-dose
DB1960-treated groups. Protein casts were present only in the
high-dose group. The splenic changes at all dose levels were lym-
phoid depletion, hemosiderosis, and proliferation of extramedul-
lary hematopoiesis (EMH). Proliferation of reticuloendothelial
(RE) cells and phagocytized (cellular) debris in RE cells were pres-
ent in the medium- and high-dose groups. Splenic lymphocyte
necrosis and hemosiderosis were present in the high-dose group,
and proliferation of RE cells was present in the medium- and
high-dose groups. Liver fatty change accompanied by decreased
hepatocytic cytoplasmic vacuolation (glycogen vacuolation) com-
pared to controls was present in all dose groups. Proliferation of
RE cells, phagocytosis of debris by RE cells, apoptosis, and hepa-
tocytic necrosis were present in high-dose-group livers. Hepatic
basophilic foci were present in medium- and high-dose groups.
At the recovery necropsy, treatment-related changes associated
with DB1955 were observed in the spleen, stomach, bone marrow,
and ileum. The forestomach in all dose groups had epithelial hy-
perplasia. Treatment-related changes associated with DB1960 at
the recovery necropsy involved the spleen, liver, duodenum, bone
marrow cytology, and bone marrow histology. The spleen had
proliferation of EMH and hemosiderosis in the low- and medium-
dose groups and phagocytized debris in RE cells in the medium-
dose group. Proliferation of EMH was observed in the livers of the
mice in the medium-dose group. The above-listed changes asso-
ciated with the test compounds were not present in all of the mice
in the various groups in which they were observed. Also, the se-
verity of the changes varied between individual mice. No test sub-
stance-related changes were present in other organs at either sac-
rifice time.
Plasma compound levels. Figure 5 shows the mean plasma
DB1955 and DB1960 concentrations on days 1 and 5. Both com-
pounds were rapidly absorbed, reaching their maximum concen-
trations 0.5 to 1 h after dose administration in most of the treat-
ment groups. In two of the DB1955 groups, however, the highest
mean concentration was reached later on day 5, at 4 h (100 mg/kg)
and 6 h (200 mg/kg). DB1955 was cleared from plasma more
rapidly than DB1960, and at 24 h after dose administration, only
the 500-mg/kg dose group displayed compound levels greater
than the LLOQ. Toxicokinetic parameter data on DB1955 and
DB1960 are presented in Table S3 in the supplemental material.
The t1/2 of DB1955 was 6.1 h and could be determined only in the
500-mg/kg dose group on day 5. The t1/2s of DB1960 were sub-
stantially longer at 18.4 h (100 mg/kg), 31.3 h (200 mg/kg), and
29.5 h (500 mg/kg). Exposure to DB1955 and DB1960, based on
TABLE 5 Clinical chemistry summary for test animals measured on day 6
Group and dose
(mg/kg/day) LDH (U/liter) AST (U/liter) ALT (U/liter) TRI (mg/dl) ALB (g/dl) AGR CHO (mg/dl) BUN (mg/dl)
Vehiclea, 0 165  45 70  7.5 40  12 181  22.8 3.9  0.17 4  0.9 90  4.6 21  2.6
DB1955
100a 155  49.3 64  9.4 35  4.7 188  52.8 3.8  0.35 3  1.1 99  6.3 22  1.9
200a 441  487.3 143  166.9 86  57.6 131  47.3 3.6  0.35 3  0.4 101  6.1 25  4.4
500a 202  73.5 75  30.6 41  27.8 119  36.6d 3.6  0.23 3  0.4 114  8.6 36  7.7
DB1960
100a 228  90 91  49.7 42  11.1 92  21.9e 3.5  0.15 3  0.5 87  6.4 22  4.2
200a 257  34.6 163  42.8 109  38.1e 64  14.3e 3.2  0.25d 2  0.0e 109  8.6 29  6.8
500b 820  422.6e 364  134.7e 91  24.7d 55  14.2c,e 3.3  0.41e 2  0.5e 129  25.7e 108  57.5e
a The values are means  standard deviations of experimental groups of five animals.
b The values are means  standard deviations of experimental groups of eight animals.
c The values are means  standard deviations of experimental groups of seven animals.
d Significant difference from control (P  0.05).
e Significant difference from control (P  0.01).
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Cmax and AUC values, increased with dose but not in a linear
fashion. AUC0-6 values were slightly higher for DB1960 than for
DB1955. The AUC0-24 is about 3-fold higher for DB1960 than for
DB1955 at a dose of 500 mg/kg.
DISCUSSION
AIAs (formerly known as reversed amidines) were inspired by
antimicrobial diamidines such as pentamidine, with the distinc-
tion that AIAs contain an imino group attached to an anilino
nitrogen rather than directly attached to an aromatic ring as in
diamidines (23). AIAs display outstanding in vitro activity against
both intracellular Leishmania (8, 22, 27) and intracellular T. cruzi
(12, 18, 19). The high potency of AIAs against these intracellular
kinetoplastid parasites could be explained in part by their lower
pKa values and higher lipophilicity than those of diamidines (27),
which may permit enhanced penetration into intracellular patho-
gens. DB766, one of the most potent AIAs in vitro, also showed
promising efficacy in a murine VL model when given orally at a
dose of 100 mg/kg/day  5 without displaying any obvious ad-
verse effects in mice or hamsters (27). Higher doses could not be
given due to the solubility of DB766. Similarly, DB766 exhibited
strong trypanocidal activity and excellent selectivity for blood-
stream trypomastigotes and intracellular amastigotes of T. cruzi
strain Y, with IC50s of 60 and 25 nM, respectively, and displayed an
efficacy similar to that of Bz in mouse models of T. cruzi infection
employing Y and Colombian strains (3). To determine whether a
higher dose and/or improved solubility could enhance the an-
tileishmanial and anti-T. cruzi efficacy of AIAs and to permit
the use of higher doses in toxicology studies aimed at determin-
ing the therapeutic windows of candidate compounds, the me-
sylate salt of DB766 (DB1960) was prepared and tested. When
evaluated in the murine VL model at an oral dose of 200 mg/
kg/day  5, DB1960 nearly eradicated liver parasitemia (Fig.
2C). For T. cruzi infection, DB1960 was also active at a 100-
mg/kg dose (Fig. 3B), resulting in a decrease in parasitemia
levels (about 50%) and protection against death (about 35%).
Although the mesylate salts were expected to possess greater
efficacy than their corresponding hydrochloride salts, a com-
parison of the in vivo antikinetoplastid efficacy and PK prop-
erties of the hydrochloride salt DB766 and its corresponding
mesylate, DB1960, indicates that DB766 possesses antiparasitic
properties superior to those of DB1960. When given at an oral
dose of 100 mg/kg/day for 5 days, DB766 inhibits liver para-
sitemia in L. donovani-infected mice by 71% (27) while
DB1960 displays 51% inhibition in this model at the same dose
(Fig. 2). Also, the maximum concentration of DB766 in the
liver after a single 100-mol/kg dose in mice (at which dose
DB766 formed a viscous solution) was 45.8 M (28), much
higher than the level of DB1960 found in the liver after the
same dose of this mesylate salt (Fig. 4B). We speculate that the
more soluble mesylate salt DB1960 may have a shorter gastro-
intestinal (GI) tract transit time than the more viscous solution
of hydrochloride salt DB766, permitting greater absorption of
the latter compound.
As shown in Fig. 4, DB1955 and DB1960 accumulate to high
concentrations in the liver and spleen, organs that harbor infec-
tion during VL. Considering that these agents achieve concentra-
tions in infected organs that are 2 orders of magnitude higher than
FIG 5 Plasma DB1955 and DB1960 levels measured after compound administration on days 1 (A and B) and 5 (C and D).
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their IC50s in the intracellular Leishmania assays, it is surprising
that liver parasitemia is not cleared in our murine VL model. This
observation is particularly puzzling for DB1960, which displays an
in vitro IC90 similar to its IC50. In VL, Leishmania parasites infect
Kupffer cells, the resident macrophages of the liver. Kupffer cells
are estimated to account for only about 2% of the liver tissue
volume, with hepatocytes comprising almost 80% (14). Since the
distribution of the AIAs within infected liver tissue is not known,
it is conceivable that the compounds do not reach the necessary
location in sufficient levels to cure parasite infections. Further
work is required to test this hypothesis.
Although the in vivo efficacies of DB1955 and DB1960 are sim-
ilar in the murine VL model (Fig. 2B and C), the same was not
observed for T. cruzi infection, given that DB1955 was inactive in
vivo despite possessing good activity in vitro (Fig. 3 and Table 2).
This could be related to the lower levels of DB1955 in the heart,
which is an important target of parasite infection and inflamma-
tion (7, 21). However, DB1960 exhibited greater toxicity than
DB1955 in mice, as illustrated by the following data. Statistically
significant changes in ALT levels were observed in the medium-
dose DB1960 group, and significant changes in BUN, ALT, AST,
and LDH levels were measured in the medium- and high-dose
DB1960 groups (Table 5). Such changes, which are indicative of
adverse effects on the kidneys and liver, were not found in any of
the DB1955 groups. At the main necropsy, discolorations in the
livers, kidneys, lymph nodes, spleens, and stomachs of the high-
dose DB1960 group, but not the high-dose DB1955 group, were
observed. Body weights of the medium- and high-dose DB1960
groups were decreased compared to those of controls at the main
necropsy, but only the high-dose DB1955 group exhibited a de-
crease in body weight. DB1960 groups, in general, displayed a
higher level of histopathological changes than the corresponding
DB1955 groups. Most importantly, the animals in the high-dose
DB1960 recovery group had to be euthanized in moribund con-
dition due to numerous adverse effects. In general, the adverse
effects of DB1960 on hematology, clinical chemistry, and the liver
and kidneys appeared to be higher than those observed for
DB1955. This could be due to the following factors. (i) DB1955
was cleared more rapidly from the plasma, as the half-life of this
compound (6.1 h) was 5-fold shorter than that of DB1960 (29.5 h)
in the 500-mg/kg group (Fig. 5; see Table S3 in the supplemental
material). (ii) Exposure levels of DB1960 were higher than those of
DB1955. The AUC0-6 value of DB1960 was slightly higher (27.09
h·g/ml) than that of DB1955 (17.37 h·g/ml), and the AUC0-24
value of DB1960 was about 3-fold higher (99.15 h·g/ml) than
that of DB1955 (36.81 h·g/ml) at the 500-mg/kg dose (see Table
S3 in the supplemental material). (iii) Metabolites were formed in
animals treated with DB1960. Three potential metabolites were
detected in day 5 plasma samples at all time points in the 500-
mg/kg DB1960 dose group, while no metabolite peaks were de-
tected in plasma collected from animals that received DB1955
(data not shown). It is possible that one or more of these DB1960
metabolites are partially responsible for the toxicity of this com-
pound. However, since individual metabolites were not identified
and evaluated for toxicity as part of this study, this cannot be
conclusively determined.
Based on the data presented here and given that irreversible
microscopic findings were also present in the GI tracts of the mice
in the low-dose treatment groups, the MTD of both DB1955 and
DB1960 is estimated to be below 100 mg/kg/day. In this study, the
NOAEL could not be determined in the 5-day repeat dose exper-
iment because adverse effects were seen at the lowest dose level
(100 mg/kg). Further development of these compounds has there-
fore been discontinued due to the lack of a therapeutic window for
existing AIAs. Nonetheless, the AIAs remain among the most ac-
tive classes of compounds against intracellular Leishmania and T.
cruzi. Our efforts to improve the efficacy and reduce the toxicity of
AIAs have resulted in the synthesis and testing of additional AIAs
containing shorter linkers (unpublished data) and AIAs contain-
ing one AIA group (mono-AIAs), as opposed to the two AIA
groups found in DB1955, DB1960, and other AIAs reported thus
far (8, 22). Within the class of AIAs containing shorter linkers, the
active compounds are toxic, with administration to mice resulting
in acute, immediate toxicity (unpublished data), unlike the com-
pounds examined here. However, none of the mono-AIA com-
pounds possessing antikinetoplastid activity that have been tested
in vivo to this point have exhibited overt toxicity to mice (X. Zhu
and T. Pandharkar, unpublished data). A better understanding of
the mechanisms of the antileishmanial and trypanocidal actions of
the AIAs along with the determination of their mammalian toxic-
ity targets could provide valuable clues for the design of new,
selective antileishmanial and anti-T. cruzi drugs. Further studies
regarding the antikinetoplastid activities and mechanisms of ac-
tion of AIAs will be reported in due course.
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